Navigation Links
ICBU Announces Corporate Reorganization and Business Plan
Date:2/8/2011

TAMPA, Fla., Feb. 8, 2011 /PRNewswire/ -- In the Third Quarter of 2010, The Board of Directors of International Coastal Biofuels (OTC MARKETS: ICBU) has elected to change the company name to iMD Companies, Inc. In addition, a new management team will take control of ICBU with the objective of propelling the company into the health and wellness arena.  The new management has opted to alter the basic structure of the firm to that of a holding company.  The new structure has the company looking for promising acquisitions in the healthcare industry and other related fields.  Saeb Jannoun has been elected Chairman of the Board of Directors as well as Chief Executive Officer.  Bruce Collett has been named Vice President and to the Board of Directors.

iMD's management will be led by serial entrepreneurs who intend to make iMD a serious player in their target areas. Management's purpose moving forward is to acquire, develop and group, promising entities under one roof, providing them with the collective power afforded by their joint assets and economies of scale.  This strategy will prove to be a profitable and financially sound platform for iMD's success.

As a first step, iMD has completed the acquisition of Integrated Medical Diagnostics, Inc.  Integrated has been performing ultrasound image analysis for over eight years using a proprietary measurement and reporting system. The company has been producing solid revenues for several years. Using a skilled team of technicians, Integrated has developed the PCI Heartscan report.  This proprietary report measures arterial lining thickness as well as arterial plaque, providing health care practitioners with a useful tool in the early detection of cardiovascular disease.

As a plus, Integrated has continued to compile a database using several statistical markers from the over 40,000 studies it has conducted.  This growing database will prove to be of great value when key data is extracted, not to mention the market value of the data itself.

The company's reorganization was approved by the Financial Industry Regulatory Association (FINRA) effective October 12, 2010.  The company was then approved and cleared the underwriting requirements under the Depository Trust & Clearing Corporation (DTCC) effective October 22, 2010.

The company has now been upgraded to fully compliant on the OTC Markets, Pinksheets Quotation Service.  "New management plans to announce its physical 2011 aggressive growth and expansion plans shortly" stated Jannoun. "We plan to state our goals clearly and concisely, and lay out a specific road map on how we plan to accomplish each and every goal, using the newest and most innovative marketing strategies created in the marketplace in the recent years. Our focus will always be on growth internally and increasing shareholder value externally," Jannoun concluded.

ABOUT IMD COMPANIES, INC.

IMD Companies, Inc., (OTC MARKETS:ICBU) is a Florida corporation, engaged in the medical diagnostics and health and fitness industries. Its primary products and services lie in the health and fitness nutraceutical and medical diagnostics services markets. The company further plans to expand into the weight-loss industry. The company delivers its medical diagnostic services on-site participating medical clinics and physician offices. The nutraceutical supplements, pills, bar and gels will be marketed and distributed through participating clinics and on-line web marketing retail methods.  The company will continue to develop its innovative marketing strategies, including the use of social networking vehicles.

Safe Harbor Statement:

Certain statements made in this press release constitute forward-looking statements that are based on management's expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. All forward-looking statements speak only as of the date of this press release and the company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.


'/>"/>
SOURCE IMD Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces License Of ACZONE® (dapsone) Gel 5% In Canada
2. 2P2D Ltd. Announces the Appointment of Tovi Bachar, Former Managing Director of GE Healthcare Israel, as Director and Chairman
3. BD Announces Results For 2011 First Fiscal Quarter
4. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
5. BD Announces Agreement to Acquire Accuri Cytometers, Inc.
6. Misonix Announces Completion of Product Registrations in Key Latin American Markets
7. ConvaTec Announces New Appointments to Leadership Team
8. Medivation Announces Participation in 13th Annual BIO CEO & Investor Conference
9. Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements
10. Fairleigh Dickinson University Announces Partnership with Medco Health Solutions, Inc. for New School of Pharmacy
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
(Date:3/27/2017)... Texas , March 27, 2017   Genprex, Inc. , ... that Julien Pham , MD, the Company,s Chief Operating Officer, ... investor conferences. Sachs 5th Annual Cancer BioPartnering & ... New York, NY ... BioCentury 24th Annual Future Leaders in ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators ... $724 million by 2022, growing at a CAGR of 3.6% during the forecast ... ... Allied Market Research Logo ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be commonplace ... injury, it occurs when the muscles around the pelvis become inflamed. Over time, ... lower torso, as well as accompanying tenderness and weakness. Without proper intervention, it ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... simulation -centric training, today announced the launch of a new research study, The ... the skills needed to execute that strategy, and the actual success of achieving ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... announce that for a second year in a row; they are the recipient ... designers in the industry voted on the award at Design Connections 2017. Top ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... ... ... The Anaheim Hills office accelerates and supports FNCC’s growth and further strengthens ... professionals over the past 6 months and is continuing to recruit new talent with ... of 2017. , “This new office is a direct result of our strong ...
Breaking Medicine News(10 mins):